Stockreport

Dario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management

DarioHealth Corp.  (DRIO) 
NASDAQ:AMEX Investor Relations: dariohealth.com/our-story
PDF As oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement [Read more]